Publications

Search our bibliography using the filters on the right-hand side.

Displaying 101 through 150 of 286 publications.

Wilburn J, McKenna S, Twiss J, Kemp K, Campbell S. Validation of the Crohn's Life Impact Questionnaire (CLIQ), the first patient-reported outcome measure specific to adults with Crohn's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A499-500. doi: 10.1016/j.jval.2013.08.1129

Wilburn J, McKenna S, Twiss J, Kemp K, Campbell S. Validating the Unidimensional Fatigue Impact Scale (U-FIS) for use in Crohn's disease. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A499. doi: 10.1016/j.jval.2013.08.1128

Messiah SE, Lopez-Mitnik G, Winegar D, Sherif BN, Arheart KL, Reichard KW, Michalsky MP, Lipshultz SE, Miller TL, Livingstone AS, de la Cruz-Muñoz N. Effect of ethnicity on weight loss among adolescents 1 year after bariatric surgery. World J Diabetes. 2013 Oct 15;4(5):202-9. doi: 10.4239/wjd.v4.i5.202

Pisa F, Castellsague J, Drigo D, Riera-Guardia N, Giangreco M, Rosolen V, Clagnan E, Zanier L, Perez-Gutthann S, Barbone F. Accuracy of International Classification of Diseases, 9th Revision, Clinical Modification codes for upper gastrointestinal complications varied by position and age: a validation study in a cohort of nonsteroidal anti-inflammatory drugs users in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Aug 20;22(11):1195-204.

Varas-Lorenzo C, Riera Guardia N, Castellsague J, Arfe A, Perez-Gutthann S. The SOS project: risk of heart failure and use of nonsteroidal anti-inflammatory drugs. A meta-analysis of observational studies. Poster presented at the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2013. [abstract] Pharmacoepidemiol Drug Saf. 22(S1):67.

MacDougall JE, Johnston JM, Lavins BJ, Nelson LM, Williams VS, Carson RT, Shiff SJ, Shi K, Kurtz CB, Baird MJ, Currie MG, Lembo AJ. An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. Neurogastroenterol Motil. 2013 Jun;25(6):481-6. doi: 10.1111/nmo.12089

Copley-Merriman K, Olanrewaju B, Hogue S. The temporal relationship between NSAIDS and risk of gastrointestinal, cardiovascular, and renal events: a systematic review. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2, 2013. [abstract] Value Health. 2013 May; 16(3):A110.

Baird MJ, Carson RT, Ervin CM, Chang L, Spiegel B, Norton NJ, Lackner J, Lasch K, Fehnel SE. Qualitative assessment of symptom experience in patients with irritable bowel syndrome for the development of patient reported outcome instruments. Poster presented at the 2013 Digestive Disease Week; May 2013.

Odom DM, Mladsi DM, Saag K, Ronquest NA, Wang J. Estimating the relationship between diclofenac drug dosage and risk of gastrointestinal toxicity: meta-regression based on a systematic literature review. Poster presented at the 2013 Digestive Disease Week; May 2013. Orlando, FL. [abstract] Gastroenterology. 2013 May; 144(5 Suppl 1):S-673. doi: 10.1016/S0016-5085(13)62496-8

Davis KL, Wang E, Dastani H, Luo A, Loftus EV. Treatment patterns, complications, and disease relapse in a real-world population of moderate-to-severe ulcerative colitis patients initiating immunosuppressive therapy. Poster presented at the 2013 Digestive Disease Week; May 2013.

Davis KL, Mody R, Rubin DT, Wang E. Association between suboptimal therapy and health care costs in inflammatory bowel disease. Poster presented at the 2013 Digestive Disease Week; May 2013.

Copley-Merriman C, Olanrewaju B, Hogue S. Systematic literature review of the temporal relationship between nsaid use and gastrointestinal, cardiovascular, or renal events. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A110.

Castellsague J, Pisa F, Rosolen V, Drigo D, Riera Guardia N, Giangreco M, Clagnan E, Tosolini F, Zanier L, Barbone F, Perez-Gutthann S. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013 Apr 22;22(4):365-75.

Ervin CM, Mangel AW. Clinical trials in irritable bowel syndrome: a review. Rev Recent Clin Trials. 2013 Mar 1;8(1):9-22.

Doward LC, Wilburn J, McKenna SP, Leicester R, Epstein O, Hedley V, Korala S, Twiss J, Jones D, Geraint M. Development and validation of the Bowel Cleansing Impact Review (BOCLIR). Frontline Gastroenterol. 2013 Feb;4(2):112-9. doi: 10.1136/flgastro-2012-100278

Seeger JD, Quinn S, Earnest DL, Lembo A, Kuo B, Rivero E. The zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterol. 2012 Dec;12(1):171.

Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S. Individual NSAIDS and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46.

Candrilli S, Davis KL, Yen L. Characteristics of diverticulitis-related emergency department visits in the United States. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A328.

Davis KL, Mitra D, Yen L. Clinical characteristics, treatment patterns, and resource utilization in a real-world European population with diverticulitis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A535-6.

Carson R, Nelson LM, Williams VS, Fehnel SE, Tourkodimitris S, Baird M, et al a. Psychometric evaluation of patient-reported outcome measures for assessing ibs-c symptom severity and change: results from 2 randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 1, 2012.

Carson R, Baird M, Coon C, Fehnel SE, MacDougall J, Nelson LM. Psychometric evaluation of patient-reported outcome measures assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Presented at the ISOQOL 19th Annual Conference; October 1, 2012.

Nelson LM, Williams VS, Carson R, Baird M, Coon C, Fehnel SE. Factor analyses of chronic constipation patient-reported outcome measures: results from phase 2b and phase 3 trials of linaclotide. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 1, 2012. Previously presented at the Joint International Neurogastroenterology and Motility Meeting.

Rubin DT, Mody R, Wang E, Davis KL. Assessment of therapy changes and drug discontinuation among crohn's disease patients using health claims data. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 2012.

Baird M, Carson R, Coon CD, Fehnel SE, MacDougall J, Nelson LM, Williams VS. Psychometric validation of patient-reported outcome measures assessing chronic constipation symptom severity: results from phase 2b and phase 3 trials of linaclotide. Poster presented at the ISOQOL 19th Annual Conference; October 2012.

Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Carson RT, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing chronic constipation symptom severity and change: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 6; 24(Suppl. s2):180.

Williams VSL, Nelson LM, Carson RT, Baird MJ, Coon CD, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBS-C): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Presented at the 2012 ACG Annual Meeting and Postgraduate Course; September 1, 2012. Previously presented at the Joint International Neurogastroenterology and Motility Meeting.

Williams VS, Nelson LM, Carson RT, Baird MJ, Coon CD, Fehnel SE. Factor analyses of patient-reported outcome measures in irritable bowel syndrome with constipation (IBS-C): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 1, 2012.

Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012 Sep 1;12(Sept):132.

Spiegel BMR, Locke G, Kurtz CM, Williams VSL, Nelson LM, Carson RT, Currie MG, Schneier HA, Johnston JM. Clinically meaningful change benchmarks for IBS-C symptoms developed using data from two phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep; 24(s2):35.

Nelson LM, Williams VS, Carson RT, Baird MJ, Coon CD, Fehnel SE. Factor analyses of chronic constipation patient-reported outcome measures: results from phase 2b and phase 3 trials of linaclotide. Presented at the Joint International Neurogastroenterology and Motility Meeting; September 1, 2012.

Nelson LM, Williams VSL, Carson RT, Baird MJ, Fehnel SE, Johnston JM. Factor analyses of patient-reported outcome measures in Irritable Bowel Syndrome with Constipation (IBSC): results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. Bologna, Italy. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):106. doi: 10.1111/j.1365-2982.2012.01997.x

Carson RT, Nelson LM, Williams VSL, Fehnel SE, Tourkodimitris S, Baird MJ, Johnston JM. Psychometric evaluation of patient-reported outcome measures for assessing IBS-C symptom severity and change: results from two randomized, double-blind, placebo-controlled phase 3 trials of linaclotide. Poster presented at the Joint International Neurogastroenterology and Motility Meeting; September 2012. [abstract] Neurogastroenterol Motil. 2012 Sep 1; 24(Suppl. 2):179.

Norquist JM, Girman C, Fehnel S, Demuro-Mercon C, Santanello N. Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration. Qual Life Res. 2012 Aug 1;21(6):1016-20.

Salvo F, Fourrier-Reglat A, Bazin F, Nicotra F, Riera Guardia N, Hagg M. The SOS project: incidences of reported cardiovascular events in RCT. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug; 21(Suppl 3):416-7.

Morton J, Sherif BN, Winegar D, Nguyen N, Ponce J, Blackstone R. National comparisons of bariatric surgery safety and efficacy: findings from the BOLD database 2007-2010. Poster presented at the 29th Annual Meeting of the American Society for Metabolic and Bariatric Surgery; June 17, 2012.

Davis KL, Yen L, Loftus E, Hodgkins P. Pre-to-postdiagnosis increase in utilization and costs of chronic-use medications and other medical resources in managed care enrollees with diverticulitis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012.

Davis KL, Yen L, Loftus EV, Hodgkins P. Pre- to post-diagnosis increase in utilization and costs of chronic-use medications and other medical resources in managed care enrollees with diverticulitis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 1, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A138.

Yen L, Davis KL, Candrilli S. The direct economic burden of diverticulitis recurrence among managed care enrollees. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. [abstract] Value Health. 2012 Jun; 15(4):A137-8.

Spiegel BMR, Locke GR, Kurtz C, Williams VS, Nelson LM, Carson RT. Developing benchmarks for clinically meaningful change for ibs-c symptoms using data from two phase 3 trials of linaclotide. Poster presented at the 2012 Digestive Disease Week; May 2012.

McKenna SP, Wilburn J, Twiss J, Ben-L'amri M, Kemp K, Campbell S. Crohn's disease: symptoms, functional limitations and quality of life. Poster presented at the 19th Annual Conference of the International Society for Quality of Life Research (ISOQOL); November 2012. Budapest, Hungary. [abstract] Qual Life Res. 2012; 21(1):103. doi: 10.1007/s11136-012-0248-x

Wilburn J, Crawford SR, McKenna SP, Twiss J, Ben-L'amri M, Kemp K, Campbell S. Assessing patient reported outcome in Crohn's disease. Poster presented at the 2012 Digestive Disorders Federation Meeting; June 2012. Liverpool. [abstract] Gut. 2012; 61(Suppl 2):391. doi: 10.1136/gutjnl-2012-302514d.229

Yen L, Davis KL, Hodgkins P, Loftus EVJr, Erder MH. Direct medical costs of diverticulitis in a US managed care population. Am J Manag Care. 2012;4(5):e118-29.

Sturkenboom M, Fourrier-Reglat A, Perez-Gutthann S, Garbe E, Nicotra F, Romio S. How to conduct collaborative studies in the EU? Lessons and results from the completed Safety of NSAIDs (SOS) Project. Pharmacoepidemiol Drug Saf. 2012;21(suppl 3):S38-9.

Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, Sturkenboom M, Perez-Gutthann S. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf. 2011 Dec 1;20(12):1225-36.

Williams VS, Nelson LM, Gilligan TM, Fehnel SE, Baird MJ, Carson RT. The relationship between changes in PRO measures of IBS-C symptoms and the IBS-QOL: results from two phase 3 trials of linaclotide. Poster presented at the 18th Annual Conference of the International Society for Quality of Life Research; October 1, 2011.

Nelson LM, Williams VS, Gilligan TN, Fehnel SE, Baird MJ, Carson RT. Examining the relationship between changes in pro measures of chronic constipation symptoms and the pac-qol: results from two phase 3 trials of linaclotide. Poster presented at the 18th Annual Conference of the International Society for Quality of Life Research; October 1, 2011.

Loftus EV, Hodgkins P, Davis KL, Yen L. Economic burden of diverticulitis complications in a Unites States managed care population. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 2011.

Chevrou-Severac H, Ochoa JB, Mauskopf JA, Candrilli SD, Graham JB, Drawert S, Greenberg N. Immunonutrition for gastrointestinal cancer patients: an effective and cost-savings intervention. Poster presented at the 24th Annual Meeting of the European Society of Intensive Care Medicine; October 2011. Previously presented at the 33rd Congress of the European Society for Clinical Nutrition and Metabolism.

Stull DE, van Hanswijck de Jonge P, Houghton K, Kocun C, Sandor DW. Development of a frequent heartburn index. Qual Life Res. 2011 Sep 1;20(7):1023-34.

Chevrou-Severac H, Mauskopf JA, Candrilli SD, Ochoa JB. Immunonutrition for gastrointestinal cancer patients: an effective and cost-savings intervention. Poster presented at the 33rd Congress of the European Society for Clinical Nutrition and Metabolism; September 2011. Gothenburg, Sweden.